argenx Announces Annual General Meeting of Shareholders on May 27, 2025 April 11, 2025, 10:01 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Tuesday, May 27, 2025 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the Annual General Meet...
Two Directors at Montea NV bought 2,450 shares at between 55.883EUR and 58.000EUR. The significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...
argenx obtained FDA approval for a PFS presentation of Vyvgart Hytrulo for self-injection for patients with AChR+ gMG or CIDP. The 20-30 second injection can now be administered by patients themselves after proper instruction, freeing them to receive treatment in healthcare settings, at home or on the go. With no specific monitoring or training requirements, the label provides a lot of flexibility for patients. We see the approval as the next phase in maintaining Vyvgart's launch momentum as it ...
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy VYVGART, the first-in-class FcRn blocker, now offers three administration options, including self-injection with a prefilled syringeSelf-injection provides gMG and CIDP patients with flexibility for when and where to receive treatment – at home, while ‘on the go’ or in a healthcare setting Approval reflects commitment to innovating the patient experience with individualized, safe and effective therapies April 10, 2025...
Solvay publishes notice of 2025 Annual General Meeting Brussels, April 10, 2025, 6:00pm CEST – Regulated information Solvay today published materials for its next Ordinary General Shareholders’ Meeting, which will be held on Tuesday May 13, 2025 at the Event Lounge Conference Center, Boulevard Général Wahis 16/F, 1030 Brussels, at 10.30 am CEST. All documents relating to this meeting are now available on . Shareholders will be asked to vote on a number of resolutions, among others: the approval of the financial statements for the financial year 2024;the approval of a total gross dividen...
Solvay publie la convocation à son Assemblée Générale annuelle de 2025 Bruxelles, le 10 avril 2025 - 18h00 CEST - Information réglementée Solvay annonce la publication des documents relatifs à sa prochaine Assemblée Générale Ordinaire, qui se tiendra le mardi 13 mai 2025 à 10h30 CEST à l’Event Lounge Conference Center situé Boulevard Général Wahis 16/F, 1030 Bruxelles. Tous les documents relatifs à cette assemblée sont désormais disponibles sur . Les actionnaires seront invités à voter sur un certain nombre de résolutions, parmi lesquelles: l’approbation des comptes annuels pour l'exerc...
Solvay publiceert oproep tot Algemene Vergadering van 2025 Brussel, 10 april 2025 - 18u00 CEST - Gereglementeerde informatie Solvay heeft vandaag de documenten voor zijn volgende Gewone Algemene Vergadering gepubliceerd. Deze zal plaatsvinden op dinsdag 13 mei 2025 in het Event Lounge Conference Center, Generaal Wahislaan 16/F, 1030 Brussel, om 10.30 uur CEST. Alle documenten met betrekking tot deze vergadering zijn nu beschikbaar op . De aandeelhouders zullen worden gevraagd te stemmen over een aantal resoluties, waaronder: de goedkeuring van de jaarrekening voor het boekjaar 2024;de go...
Trumps reciprocal tariffs caused a massive blow to equity markets, following a pressured period of escalating trade wars. Retaliatory measures can further heavily damage market confidence, as seen Friday when China announced their 34% tarrif of US goods. International trade policies have never moved this erratic and untransparant, with uncertainty and volatility being the baseline for now. In this report we highlight the key stocks in our coverage relevant to this discussion.
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP ADAPT-NXT data demonstrate consistent, sustained disease control across dosing schedules, further supporting individualized VYVGART dosing for gMG patients ADHERE+ oral presentation features long-term CIDP data demonstrating VYVGART Hytrulo’s durable efficacy, sustained functional improvements and favorable safety profileargenx continues to advance a robust neuromuscular pipeline of clinical candidates; first-in-human data of ARG...
KPN reports on progress of € 250m share buyback KPN has repurchased 1,660,000 KPN ordinary shares in the period from 31 March to 4 April 2025. The shares were repurchased at an average price of € 3.96 per share for a total consideration of € 6.6m. These repurchases are part of the € 250m share buyback started on 25 February 2025 and reflect KPN's commitment to structurally return additional capital to its shareholders. The total number of ordinary shares repurchased to date is 11,114,964 for a total consideration of € 42.0m. Transaction details of the share buyback are available on our . ...
Solvay releases its 2024 annual integrated report In 2024, Solvay introduced its “Essential for generations” strategy, delivered solid performance and launched the “For Generations” sustainability roadmap Brussels, April 3, 2025 - 6:00 pm CEST Solvay has released its Annual Integrated Report, which provides an overview of the company’s financial, environmental, and societal performance for 2024. This comprehensive document serves as a key reference for stakeholders, highlighting Solvay's new strategy as a leader in essential chemistry and how Solvay will deliver on it. It also pr...
Solvay publie son rapport annuel intégré 2024 En 2024, Solvay a présenté sa stratégie « Essential for generations », a enregistré de solides performances et a lancé la feuille de route de développement durable « For Generations » Bruxelles, le 3 avril 2025 - 18h00 CEST Solvay a publié son rapport intégré annuel, qui donne un aperçu des performances financières, environnementales et sociétales de l'entreprise pour l'année 2024. Ce document exhaustif sert de référence clé pour les parties prenantes, mettant en avant la nouvelle stratégie de Solvay en tant que leader dans le domaine de...
Solvay publiceert geïntegreerd jaarverslag 2024 In 2024 introduceerde Solvay zijn "Essentieel voor generaties" strategie, leverde solide prestaties en lanceerde de "For Generations" duurzaamheidsroadmap Brussel, 3 april 2025, om 18u00 CEST Solvay publiceerde zijn geïntegreerd jaarverslag, dat een overzicht geeft van de financiële, milieu- en maatschappelijke prestaties van de onderneming voor 2024. Dit uitgebreide document dient als een belangrijk referentiepunt voor belanghebbenden, waarbij de nieuwe strategie van Solvay als leider in essentiële chemie wordt benadrukt en hoe Solvay ...
Two Directors at NN Group NV sold 10,081 shares at between 50.660EUR and 52.030EUR. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.